Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 35,100 shares of the firm’s stock in a transaction on Friday, July 28th. The shares were purchased at an average cost of $6.30 per share, with a total value of $221,130.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $19,334,391.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, August 10th, Phillip Md Et Al Frost bought 39,000 shares of Opko Health stock. The stock was acquired at an average cost of $6.23 per share, with a total value of $242,970.00.
  • On Wednesday, August 9th, Phillip Md Et Al Frost bought 18,000 shares of Opko Health stock. The stock was acquired at an average cost of $6.35 per share, with a total value of $114,300.00.
  • On Tuesday, August 8th, Phillip Md Et Al Frost bought 5,000 shares of Opko Health stock. The stock was acquired at an average cost of $6.05 per share, with a total value of $30,250.00.
  • On Wednesday, August 2nd, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The stock was acquired at an average cost of $6.15 per share, with a total value of $153,750.00.
  • On Tuesday, August 1st, Phillip Md Et Al Frost bought 46,600 shares of Opko Health stock. The stock was acquired at an average cost of $6.25 per share, with a total value of $291,250.00.
  • On Thursday, July 27th, Phillip Md Et Al Frost bought 23,600 shares of Opko Health stock. The stock was acquired at an average cost of $6.34 per share, with a total value of $149,624.00.
  • On Wednesday, July 26th, Phillip Md Et Al Frost bought 36,200 shares of Opko Health stock. The stock was acquired at an average cost of $6.39 per share, with a total value of $231,318.00.
  • On Tuesday, July 25th, Phillip Md Et Al Frost acquired 39,800 shares of Opko Health stock. The shares were purchased at an average price of $6.41 per share, with a total value of $255,118.00.
  • On Monday, July 24th, Phillip Md Et Al Frost acquired 45,000 shares of Opko Health stock. The shares were purchased at an average price of $6.42 per share, with a total value of $288,900.00.
  • On Thursday, July 20th, Phillip Md Et Al Frost acquired 5,400 shares of Opko Health stock. The shares were purchased at an average price of $6.46 per share, with a total value of $34,884.00.

Shares of Opko Health, Inc. (NASDAQ OPK) traded up 2.13% during midday trading on Friday, hitting $6.24. The stock had a trading volume of 4,707,786 shares. The firm’s market capitalization is $3.49 billion. Opko Health, Inc. has a 1-year low of $5.99 and a 1-year high of $12.15. The company’s 50 day moving average price is $6.38 and its 200-day moving average price is $7.28.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The company had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. During the same quarter in the prior year, the company earned $0.02 EPS. The firm’s revenue was down 12.0% on a year-over-year basis. Equities analysts predict that Opko Health, Inc. will post ($0.20) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/08/12/phillip-md-et-al-frost-buys-35100-shares-of-opko-health-inc-opk-stock-updated.html.

A number of large investors have recently bought and sold shares of the stock. Financial Architects Inc raised its stake in Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,800 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Opko Health during the fourth quarter worth approximately $105,000. Blair William & Co. IL purchased a new stake in Opko Health during the second quarter worth approximately $112,000. Timber Hill LLC purchased a new stake in Opko Health during the first quarter worth approximately $114,000. Finally, Comerica Bank purchased a new stake in Opko Health during the fourth quarter worth approximately $117,000. Institutional investors own 23.05% of the company’s stock.

OPK has been the subject of several recent research reports. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a report on Thursday, May 4th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $19.50 price objective on shares of Opko Health in a report on Friday, June 16th. BidaskClub upgraded Opko Health from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Jefferies Group LLC reiterated a “hold” rating and set a $8.00 price objective on shares of Opko Health in a report on Monday, June 12th. Finally, Barrington Research raised their target price on Opko Health to $11.00 and gave the company an “outperform” rating in a report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $14.61.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.